...cancer early onset (BRCA) mutations NewLink Genetics Corp. (NASDAQ:NLNK) $19.26 18% Ph II data show tergenpumatucel-L...

...NewLink began an open-label Phase IIb/III trial to compare 2 dosing schedules of tergenpumatucel-L at 300...
...tergenpumatucel-L for 11 weeks and then every 2 months for an additional 5 doses or tergenpumatucel-L...
...the final enrollment in the trial. NewLink Genetics Corp. (NASDAQ:NLNK), Ames, Iowa Product: Tergenpumatucel-L ( HyperAcute Lung...

...Phase II portion of a single-arm, open-label Phase I/II trial in 54 patients showed that HyperAcute Lung...
...most common treatment-related adverse events reported were skin reactions at the injection site. Patients received HyperAcute Lung...
...data from the 28 patients in the Phase II portion of the trial showing that HyperAcute Lung...

...also plans to use $18 million to start and complete a Phase III trial of HyperAcute Lung...

...Phase II portion of a single-arm, open-label Phase I/II trial in 54 patients showed that HyperAcute Lung...
...of 52.1 weeks (see BioCentury, April 26, 2010). NewLink Genetics Corp. , Ames, Iowa Product: HyperAcute Lung...

...see BioCentury, June 14, 2010 ). The company has other clinical-stage cancer vaccines, including HyperAcute Lung...

...Phase I portion of a U.S. Phase I/II trial in 16 evaluable patients showed that HyperAcute Lung...
...American Association for Cancer Research meeting in Washington. NewLink Genetics Corp. , Ames, Iowa Product: HyperAcute Lung...

...raising a total of $30 million. The investors were not disclosed. NewLink's HyperAcute Pancreas and HyperAcute Lung...